A Double-blind, Randomized, Adaptive Design, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar 2 mg and 4 mg Tablets Versus Placebo for Treating Women with Polycystic Ovary Syndrome (PCOS)
Latest Information Update: 16 Jun 2020
At a glance
- Drugs Saroglitazar (Primary)
- Indications Polycystic ovary syndrome
- Focus Therapeutic Use
- Sponsors Zydus Lifesciences
Most Recent Events
- 19 May 2020 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2019 New trial record